On July 26, 2021 Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MOLCURE Inc., reported they generated potent, binding antibodies to an undisclosed oncology target for Twist’s internal pipeline of antibody candidates (Press release, Twist Bioscience, JUL 26, 2021, View Source [SID1234585196]). The collaborative research project resulted from a technology agreement between the companies to pursue novel antibody targets through Twist’s antibody discovery and optimization together with MOLCURE’s AI technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are proud to have engaged in collaborative research with Twist Bioscience, selected by Fast Company as one of the most innovative companies in 2021," said Ryu Ogawa, Ph.D., CEO of MOLCURE. "Our expectations that this would reinforce our partner’s therapeutic antibody pipelines and further strengthen our AI driven molecule design service were confirmed in this project."

"Twist Bioscience continues to innovate and incorporate the most advanced methods of antibody discovery and optimization into our processes," said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "MOLCURE’s AI approach complements our proprietary antibody discovery and optimization efforts, leveraging technology to refine our internal antibody pipeline. Their platform enables us to find more leads derived from NGS sequencing from our library. We look forward to taking leads generated from this collaboration forward within our internal pipeline."